1. Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol. 1994; 18:535–58.
2. Amant F, Moerman P, Vergote I. Report of an unusual problematic uterine smooth muscle neoplasm, emphasizing the prognostic importance of coagulative tumor cell necrosis. Int J Gynecol Cancer. 2005; 15:1210–2.
Article
3. Guntupalli SR, Ramirez PT, Anderson ML, Milam MR, Bodurka DC, Malpica A. Uterine smooth muscle tumor of uncertain malignant potential: a retrospective analysis. Gynecol Oncol. 2009; 113:324–6.
Article
4. Kalogiannidis I, Stavrakis T, Dagklis T, Petousis S, Nikolaidou C, Venizelos I, et al. A clinicopathological study of atypical leiomyomas: benign variant leiomyoma or smooth-muscle tumor of uncertain malignant potential. Oncol Lett. 2016; 11:1425–8.
Article
5. Mowers EL, Skinner B, McLean K, Reynolds RK. Effects of morcellation of uterine smooth muscle tumor of uncertain malignant potential and endometrial stromal sarcoma: case series and recommendations for clinical practice. J Minim Invasive Gynecol. 2015; 22:601–6.
Article
6. Ip PP, Cheung AN, Clement PB. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases. Am J Surg Pathol. 2009; 33:992–1005.
7. Shapiro A, Ferenczy A, Turcotte R, Bruchim I, Gotlieb WH. Uterine smooth-muscle tumor of uncertain malignant potential metastasizing to the humerus as a high-grade leiomyosarcoma. Gynecol Oncol. 2004; 94:818–20.
Article
8. Ng JS, Han A, Chew SH, Low J. A clinicopathologic study of uterine smooth muscle tumours of uncertain malignant potential (STUMP). Ann Acad Med Singapore. 2010; 39:625–8.
9. Croce S, Young RH, Oliva E. Uterine leiomyomas with bizarre nuclei: a clinicopathologic study of 59 cases. Am J Surg Pathol. 2014; 38:1330–9.
10. Dall'Asta A, Gizzo S, Musarò A, Quaranta M, Noventa M, Migliavacca C, et al. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): pathology, follow-up and recurrence. Int J Clin Exp Pathol. 2014; 7:8136–42.
11. Croce S, Ribeiro A, Brulard C, Noel JC, Amant F, Stoeckle E, et al. Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions. Mod Pathol. 2015; 28:1001–10.
Article
12. Bacanakgil BH, Deveci M, Karabuk E, Soyman Z. Uterine smooth muscle tumor of uncertain malignant potential: clinicopathologic-sonographic characteristics, follow-up and recurrence. World J Oncol. 2017; 8:76–80.
Article
13. Maltese G, Fontanella C, Lepori S, Scaffa C, Fucà G, Bogani G, et al. Atypical uterine smooth muscle tumors: a retrospective evaluation of clinical and pathologic features. Oncology. 2018; 94:1–6.
Article
14. Basaran D, Usubutun A, Salman MC, Narin MA, Boyraz G, Turkmen O, et al. The clinicopathological study of 21 cases with uterine smooth muscle tumors of uncertain malignant potential: centralized review can purify the diagnosis. Int J Gynecol Cancer. 2018; 28:233–40.
15. Soltan MM, Albasry AM, Eldosouky MK, Abdelhamid HS. Immunoexpression of progesterone receptor, epithelial growth factor receptor and galectin-3 in uterine smooth muscle tumors. Cell Mol Biol. 2018; 64:7–12.
Article
16. Conconi D, Chiappa V, Perego P, Redaelli S, Bovo G, Lavitrano M, et al. Potential role of BCL2 in the recurrence of uterine smooth muscle tumors of uncertain malignant potential. Oncol Rep. 2017; 37:41–7.
Article
17. Cao HY, Yang S, Wang S, Deng LY, Lou JY. Is differential expression of p16INK4a based on the classification of uterine smooth muscle tumors associated with a different prognosis? A meta-analysis. Genet Mol Res. 2017; 16:16.
Article
18. Hewedi IH, Radwan NA, Shash LS. Diagnostic value of progesterone receptor and p53 expression in uterine smooth muscle tumors. Diagn Pathol. 2012; 7:1.
Article
19. O'Neill CJ, McBride HA, Connolly LE, McCluggage WG. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential. Histopathology. 2007; 50:851–8.
20. Atkins KA, Arronte N, Darus CJ, Rice LW. The Use of p16 in enhancing the histologic classification of uterine smooth muscle tumors. Am J Surg Pathol. 2008; 32:98–102.
Article
21. Ünver NU, Acikalin MF, Öner Ü, Ciftci E, Ozalp SS, Colak E. Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors. Arch Gynecol Obstet. 2011; 284:483–90.
Article
22. Croce S, Ducoulombier A, Ribeiro A, Lesluyes T, Noel JC, Amant F, et al. Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors. Mod Pathol. 2018; 31:816–28.
Article
23. Dgani R, Piura B, Ben-Baruch G, Open M, Glezerman M, Nass D, et al. Clinical-pathological study of uterine leiomyomas with high mitotic activity. Acta Obstet Gynecol Scand. 1998; 77:74–7.
Article
24. Vilos GA, Marks J, Ettler HC, Vilos AG, Prefontaine M, Abu-Rafea B. Uterine smooth muscle tumors of uncertain malignant potential: diagnostic challenges and therapeutic dilemmas. Report of 2 cases and review of the literature. J Minim Invasive Gynecol. 2012; 19:288–95.
Article
25. Takeda A, Imoto S, Mori M, Nakamura H. Successful pregnancy outcome after laparoscopic-assisted excision of a bizarre leiomyoma: a case report. J Med Case Reports. 2011; 5:344.
Article
26. Campbell JE, Knudtson JF, Valente PT, Robinson RD, Kost ER. Successful pregnancy following myomectomy for uterine smooth muscle tumor of uncertain malignant potential: a case report and review of the literature. Gynecol Oncol Rep. 2015; 15:1–3.
Article
27. Ha HI, Choi MC, Heo JH, Kim KA, Jung SG, Park H, et al. A clinicopathologic review and obstetric outcome of uterine smooth muscle tumor of uncertain malignant potential (STUMP) in a single institution. Eur J Obstet Gynecol Reprod Biol. 2018; 228:1–5.
Article
28. Hughes L, Roex A, Parange A. STUMP, a surprise finding in a large fibroid uterus in a 20-year-old woman. Int J Womens Health. 2018; 10:211–4.
Article